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o r i g i n a l a r t i c l e
Case-Control Study of Surgical Site Infections Associated
With Pacemakers and Implantable Cardioverter-Defibrillators
Jonas Marschall, MD; Diane Hopkins-Broyles, RN; Marilyn Jones, RN;
Victoria J. Fraser, MD; David K. Warren, MD, MPH
objective. In 2000, the rate of surgical site infections (SSIs) associated with pacemaker and implantable cardioverter-defibrillator (ICD)
procedures performed in the cardiothoracic operating rooms of hospital A was 16% (19 of 116 procedures resulted in infections). This
study investigates risks for SSI associated with these procedures in the cardiothoracic operating room.
design. Unmatched 1 : 3 case-control study performed over a 12-month period among patients who had undergone implantation of a
pacemaker and/or ICD. A standardized observation scrutinized infection control practices in the area where the procedures were performed.
setting. The cardiothoracic operating rooms of hospital A, which belongs to a hospital consortium in the midwestern United States.
patients. Patients with SSI were identified as case patients. Control patients were chosen from the group of uninfected patients who
had procedures performed during the same period as case patients.
results. A total of 19 SSIs associated with pacemaker and ICD procedures were retrospectively identified among the patients who
underwent procedures in these cardiothoracic operating rooms. Culture samples were obtained from 7 patients; 2 yielded coagulase-negative
Staphylococcus on culture, 2 yielded Staphylococcus aureus, 1 yielded Serratia marcescens, and 2 showed no growth. In the case-control study,
age, race, sex, diabetes mellitus, smoking history, timing of antibiotic therapy, and hair removal did not differ significantly between case
patients and control patients. Case patients were more likely to have an abdominal device in place (odds ratio [OR], 5.5 [95% confidence
interval {CI}, 1.6-19.3]; ) and less likely to have received a new implant (OR 0.3 [95% CI, 0.1-0.8]; ) or to have had newPp .006 Pp .02
leads placed (OR, 0.2 [95% CI, 0.1-0.6]; ).Pp .003
conclusions. Abdominal placement of implanted devices was associated with occurrence of an SSI after pacemaker and/or ICD
procedures.
Infect Control Hosp Epidemiol 2007; 28:1299-1304
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The use of cardiac pacemakers and implantable cardioverter-
defibrillators (ICDs) has increased considerably, because they
reduce the incidence of both cardiac symptoms and sudden
death in patients with arrhythmias.1,2 In recent years, there
has also been an expansion of indications for their use. Ac-
cording to a worldwide survey regarding implantable cardiac
device use, 223,226 pacemakers and 48,127 ICDs were im-
planted in patients who underwent such placement proce-
dures in the United States in 2001.3
Along with their increased use there have been increasing
reports of infections associated with cardiac devices. In a
survey of Medicare beneficiaries, there was a 124% increase
in infections associated with cardiac devices between 1990
and 1999.4 This increase in infections is out of proportion to
the increase in the number of device implantation procedures
performed during the same period. Among the possible ex-
planations for this increase are a higher mean age at im-
plantation5 and a longer time at risk for infection due to
longer survival of device recipients.4 A higher number of
underlying comorbidities in patients or changes in insertion
practices might also play a role, as may increased awareness
and reporting of infection.
There are several risk factors that have been linked to the
development of surgical site infections (SSIs) and specifically
to infections associated with cardiac devices. Reported risk
factors for infection include congestive heart failure, diabetes
mellitus, renal insufficiency and the frequency with which
generators are exchanged.6 The experience level of the person
inserting the device has also been shown to influence the risk
of infection.7
Overall infection rates for implantable cardiac device pro-
cedures have been reported to be in the range of 0.5%-5.1%.8
However, infection rates in patients receiving ICDs are less
well studied because these devices have been more recently
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introduced into cardiac therapy.9,10 Infections associated with
cardiac devices have been shown to cause substantial mor-
bidity and they can lead to dramatic increases in healthcare
costs, ranging from $10,000 to $40,000 per patient.11
Only a few case-control studies on infections associated
with cardiac devices have been published. The purpose of this
study was to provide a detailed account of infections asso-
ciated with pacemaker and ICD procedures and the related
risks by means of a case-control study in a hospital within
an integrated healthcare system that had an increased rate of
pacemaker- and ICD-associated SSI.
methods
Setting and Patient Population
Hospital A is a hospital within BJC Healthcare, a consortium
of 13 hospitals in the midwestern United States with a catch-
ment area including the eastern part of Missouri and the
southwestern part of Illinois. One of the authors (D.H.-B.)
collected the data for this study.
Cardiac devices are implanted at hospital A either by car-
diac surgeons in 1 of 3 cardiothoracic operating rooms or by
interventional cardiologists in 1 of 3 cardiac catheterization
laboratories. Procedures that are expected to be complicated
(eg, removal of tightly implanted leads or procedures in-
volving critically ill or clinically unstable patients) tend to be
performed in the operating rooms. In 2000, there were 622
cardiac devices implanted at this hospital; 116 (19%) of these
procedures were performed in the operating rooms and 506
(81%) in the cardiac catheterization laboratories.
Case Series Investigation
In January 2001, the BJC Healthcare Infection Control and
Healthcare Epidemiology Consortium was notified by the car-
diology service about a cluster of infections in patients who
had had pacemakers or ICDs inserted in the cardiothoracic
operating rooms during the period from January to December
2000. Up to that time, no focused surveillance for cardiac
device–associated infections had been performed in any BJC
Healthcare hospitals. In contrast, no increased rate of infec-
tion had been reported from the catheterization laboratories.
Subsequently, an extensive search to retrospectively identify
case patients with cardiac device–associated infections was
performed, including a review of microbiology laboratory
reports, a query regarding readmissions for infection among
patients who received a pacemaker and/or ICD, and notifi-
cation by the cardiology and cardiothoracic services of in-
fected patients seen in their offices. Infected case patients were
defined using standard Centers for Disease Control and Pre-
vention National Nosocomial Infections Surveillance System
definitions12 and included those who had had a device placed
at hospital A prior to infection. Briefly, SSIs were classified
as superficial incisional, deep incisional, or organ space in-
fections, depending on whether an infection was in the skin
and subcutaneous tissue, in the fascia and muscle layer, or
in deeper tissues. The further investigation of cardiac device–
associated infections included the observation of infection
control practices in the cardiothoracic operating rooms. Ob-
servations were performed using a standardized data collec-
tion instrument.
The study was approved by the Washington University
institutional review board.
Case-Control Study
To better identify risk factors associated with the development
of SSI in the study population, a 1 : 3 case-control study was
performed. A random control population of 57 patients who
had procedures to place implantable cardiac devices per-
formed in the cardiothoracic operating rooms during the
same period as the case patients, but who did not develop
infections, were chosen for comparison. Data for both case
and control patients were collected using a standardized data
collection tool. Demographic information was collected, as
was information about risk factors for infection, including
diabetes mellitus, overweight status (ie, body mass index of
25 or greater), the presence of a previous implant, the site
of any cardiac device implant, American Society of Anesthe-
siologists (ASA) score, receipt of preoperative showers, pre-
operative and postoperative antibiotic therapy, length of sur-
gery, type of device implanted, irrigation fluid used, and the
individual surgeon who implanted the device.
Infection Control Measures
To ensure the establishment of proper infection control tech-
niques in the cardiothoracic operating rooms, several inter-
ventions were implemented. First, in-service training about
appropriate skin preparation for the operating room staff was
conducted. Second, the technique that the manufacturers’
representatives used to pass devices to the operating physi-
cians was reviewed and improved. Third, prospective sur-
veillance for SSI in patients receiving implantable cardiac de-
vices was initiated in January 2001 and continued until March
2002.
Analysis
The ASA score was used to define the clinical condition of
patients at the time the device was implanted. Microsoft Excel
2003 (Microsoft) was used for data entry and for calculation
of means and confidence intervals. For the statistical analysis,
SPSS, version 11.0 (SPSS), was used. A 2-sided P value less
than .05 was considered statistically significant.
results
Case Patients
The overall rate of infections associated with pacemaker and/
or ICD procedures performed in the cardiothoracic operating
rooms during the study period was 16%; there were 19 in-
fections among 116 patients who underwent surgery. Of the
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19 infections, 12 were superficial and 7 were deep incisional
infections. Of patients with SSI, culture samples were ob-
tained only from the 7 patients (37%) with deep infections.
The organisms identified on culture were coagulase-negative
Staphylococcus species (2 samples), Staphylococcus aureus (1),
and Serratia marcescens (1); there were 2 samples that yielded
no growth on culture. Prior to infection, 11 (58%) of these
19 patients had a cardiac device removed and a new device
placed in the same surgical pocket. Of the remaining 8 pa-
tients (42%), a total of 7 had a device placed in a new site
and 1 underwent a first-time device placement. Of the 7
patients who had a pacemaker and/or ICD replaced in a new
site, 3 had an infection at the explant site and 4 had an
infection at the new surgical pocket. The median time until
development of infection was 9 days (range, 7-222 days). The
mean age (SD) of the case patients was years.60.0 16.3
Seventy-nine percent of the case patients were male and 90%
were white.
Observation in Operating Rooms
Observations in the cardiothoracic operating rooms revealed
instances of inadequate skin preparation technique as well as
pacemaker manufacturers’ representatives reaching across the
sterile field to hand off devices, potentially contaminating the
surgical site.
Risk Factor Analysis in the Case-Control Study
There were no significant differences in age, sex, or race be-
tween case and control patients (Table). Only a few (11%)
of the case patients had documentation of a preoperative
shower in their records (11% of control patients had similar
documentation). Interestingly, case patients were somewhat
more likely to be outpatients at the time of the procedure,
compared with control patients ( ).Pp .06
The majority of patients in both groups (16 [84%] of 19
case patients and 43 [75%] of 57 control patients) received
perioperative antibiotic prophylaxis in a timely manner, that
is, within 30-120 minutes before incision. There was no sig-
nificant difference between the 2 groups with respect to this
factor ( ).Pp .53
Case patients were less likely to have undergone procedures
involving implantation of a new device, compared with con-
trol patients (42% vs 74%; ), or to have undergonePp .02
placement of only new leads (32% vs 72%; ). CasePp .003
patients were, however, more likely to have an abdominal
cardiac device in situ at the time of surgery, compared with
control patients (74% vs 33%; ). The rate of reten-Pp .006
tion of leads was not significantly different between case and
control patients (21% vs 26%; ).Pp .77
Changes in Recommendations and Policy
As a result of the increase in the incidence of infection during
2000, the following recommendations were made to improve
practices and reduce the risk of infection: (1) ensure timely
administration of preoperative antibiotics prior to incision,
(2) ensure preoperative shower with an antimicrobial soap,
(3) ensure adequate skin preparation, and (4) obtain wound
culture samples from patients who have wound or device
drainage after cardiac devices are placed prior to initiation
of antibiotics.
Subsequently, prospective surveillance for SSI following
placement of implantable cardiac devices in the cardiotho-
racic operating rooms was initiated. Case patients were iden-
tified by communication with the cardiothoracic clinic, the
cardiology clinic, by readmission reports, and by microbi-
ology laboratory data. From January 2001 through March
2002, there were 7 infections identified following 93 proce-
dures (infection rate, 8%).
discussion
The number of studies on SSI associated with implantable
cardiac devices has increased in recent years.13,14 This reflects
the increasing size of the problem because more and more
pacemakers and ICDs are implanted in the United States.4
However, to our knowledge, few of these studies have in-
vestigated the risk factors for infection by means of a case-
control study.6 We give a detailed account of an infection
control investigation and the risk factors associated with the
development of SSI in patients who received pacemakers and
ICDs. In brief, the infection investigation found that aspects
of preoperative skin preparation and antibiotic prophylaxis,
and procedures involving an in situ abdominal device, were
significantly associated with subsequent infection.
The overall rate of infection in patients who received im-
plantable cardiac devices observed in this study was 16%.
This rate is above the range of infection rates in the recent
literature, which has been reported as 0.4%-5.4% for
pacemakers15,16 and 0.2%-5.7% for ICDs.17,18 However, infec-
tion rates after pacemaker implantation as high as 19.9% were
reported in the 1970s, which were related to abdominal im-
plantation.19 In the last 2 decades, however, a transition to
prepectoral implantation for most cardiac devices has taken
place, and rates of infection have been lower in comparison.20
In the current study, implantation of a device in the ab-
dominal wall was strongly associated with an increased risk
of infection ( ). This finding correlates with the find-Pp .006
ings of Mela et al.,20 who found a higher rate of infection
associated with abdominal placement (3.2%), compared with
pectoral placement (0.5%). Possible explanations are differ-
ences in the vascular supply, the adipose tissue, and the local
skin flora.
A small percentage of patients in our study (11%) had
documentation of receiving a preoperative shower with an
antiseptic solution. Explanations for this low rate might be
deficits in the instruction of patients, deficits in patient com-
pliance, or simply inadequate documentation of established
practices. The efficacy of a chlorhexidine gluconate solution
as a skin antiseptic was demonstrated by Paulson,21 who
table. Comparison of Demographic Characteristics and Risk Factors for Cardiac Device-Associated







OR (95% CI) P
Age, mean  SD, years 60  16.3 63  16.2 .4
White race 17 (90) 49 (86) 1.4 (0.2-10.5) .99
Male sex 15 (79) 33 (58) 2.7 (0.7-11.2) .2
Smoking status
Current 1 (5) 7 (12) 0.4 (0.1-3.5) .7
Former 8 (42) 26 (46) 0.9 (0.3-2.5) .99
Overweight (BMI x25) 5 (26) 12 (22) 1.3 (0.4-4.3) .99
Diabetes mellitus 7 (37) 14 (25) 1.8 (0.6-5.4) .99
Previous implant 17 (90) 42 (74) 3.0 (0.6-14.7) .2
Outpatient prior to procedure 14 (74) 27 (47) 3.1 (0.99-9.8) .06
Received preoperative shower 2 (11) 6 (11) 1.0 (0.2-5.4) .5
Preoperative antibiotic prophylaxis received
Vancomycin 4 (21) 11 (19) 1.1 (0.3-4.0) .99
Cefazolin 15 (79) 44 (77) 1.1 (0.3-3.9) .99
Not documented 0 2 (4)
Timely preoperative antibiotic prophylaxisa 16 (84) 43 (75) 1.7 (0.4-8.8) .5
Body hair removed with electric shaving 10 (53) 17 (30) 2.6 (0.8-8.7) .1
Skin prepared with tincture of iodineb 10 (53) 20 (35) 2.1 (0.7-5.9) .2
ASA score
2 1 (5) 3 (5) Reference
3 14 (74) 37 (65) 1.1 (0.1-11.8) .99
4 4 (21) 17 (30) 0.7 (0.1-8.7) .99
Operating room where surgery took place
A 3 (16) 5 (9) 2.0 (0.4-9.1) .99
B 9 (47) 32 (56) 0.7 (0.3-2.0) .6
C 4 (21) 14 (25) 0.8 (0.2-2.9) .99
Received general anesthesia 18 (95) 50 (88) 2.5 (0.3-21.9) .7
Device type received
ICD 11 (58) 19 (33) 2.8 (0.95-8.0) .7
Pacemaker 6 (32) 21 (37) 0.8 (0.3-2.4) .8
Procedure undergonec
Surgical pocket revision 4 (21) 10 (18) 1.3 (0.3-5.3) .7
Generator change 10 (53) 16 (28) 2.8 (0.98-8.3) .09
Device removal 8 (42) 29 (51) 0.7 (0.3-2.0) .6
Lead removal 7 (37) 26 (46) 0.7 (0.2-2.0) .6
New implant 8 (42) 42 (74) 0.3 (0.1-0.8) .02
New lead placement 6 (32) 41 (72) 0.2 (0.1-0.6) .003
Device location
Same sited
Pectoral 3 (16) 23 (40) 0.3 (0.1-1.1) .2
Abdominal 8 (42) 11 (19) 3.0 (0.9-10.8) .07
Abdominal site
Olde 14 (74) 19 (33) 5.5 (1.6-19.3) .006
New 8 (42) 12 (21) 2.5 (0.8-7.8) .99
Moved from abdominal to pectoral 6 (32) 8 (14) 2.8 (0.8-9.6) .99
Old leads retained 4 (21) 15 (26) 0.8 (0.2-2.6) .8
Radiography used intraoperatively 6 (32) 21 (37) 0.8 (0.3-2.4) .8
Laser used intraoperatively 3 (16) 21 (37) 0.3 (0.1-1.2) .2
(Continued)








OR (95% CI) P
Fluoroscopy 8 (42) 30 (53) 0.7 (0.2-1.9) .4
Irrigation fluid used
Any 19 (100) 52 (91) … …
With antibiotics 18 (95) 51 (90) 2.1 (0.2-18.8) .7
With vancomycin 4 (21) 8 (14) 1.6 (0.4-6.2) .99
Closure method
Sutures plus adhesivef 7 (37) 13 (23) 2.0 (0.7-6.0) .99
Sutures only 13 (68) 44 (77) 0.6 (0.2-2.0) .99
Mean procedure time, min 42.6 35.7 .3
IV antibiotic therapy after surgery 9 (47) 37 (65) 0.5 (0.2-1.4) .2
Antibiotic therapy after discharge 5 (26) 13 (23) 1.2 (0.4-4.0) .99
note. Data are no. (%) of patients, unless otherwise indicated. ASA, American Society of Anesthesiologists; BMI,
body mass index; CI, confidence interval; ICD, implantable cardioverter-defibrillator; IV, intravenous; OR, odds ratio.
a Administered 30-120 minutes before incision.
b Versus other formulations, eg, povidone-iodine (with 0.75% available iodine).
c Patients could undergo multiple procedures (ie, the categories are not mutually exclusive).
d Patients who had a device removed and new device placed in the same site.
e When patient went to the OR, the device was abdominally placed (ie, the old site was abdominal).
f Cyanoacrylate tissue adhesive (Dermabond; Ethicon) used to replace or reinforce conventional sutures.
showed significant reduction in the concentration of micro-
bial flora on healthy volunteers after using chlorhexidine glu-
conate body washes. Seal et al.22 advocated the inclusion of
such an antiseptic shower as part of a system of prevention
before surgery, and the procedure has been advocated by
national guidelines.23 However, chlorhexidine gluconate was
not found to reduce the incidence of SSI in a recent meta-
analysis of existing studies.24
Twenty-two percent of the study population did not receive
timely perioperative antibiotic prophylaxis (ie, within 30-120
minutes prior to incision).25 Antibiotic prophylaxis is an es-
tablished part of the standard-of-care to prevent SSI23 and a
meta-analysis has previously shown it to be efficient in re-
ducing the incidence of SSIs in pacemaker recipients.26 Rea-
sons for the suboptimal timing of antibiotic prophylaxis may
include anesthesiologists’ lack of awareness of the importance
of reducing the microbial load perioperatively, insufficient
processes for ensuring preoperative administration of anti-
biotics, or failure to document administration properly. On
the basis of substantial evidence of inconsistent perioperative
administration of antibiotics, the Institute for Healthcare Im-
provement is advocating the intransigent and healthcare-wide
implementation of ideal perioperative care practices to reduce
the risk of SSI.27
Only a third of infected patients (37%) had wound cultures
performed, which precluded a detailed examination of the
microbiology of these infections. It is not surprising that co-
agulase-negative staphylococci and S. aureus were found in
4 of the 7 infections for which culture samples were obtained.
These bacteria are the most common causes of cardiac device–
associated infections.28 We have no detailed information
about the 2 case patients who had negative culture results.
One explanation might be that they had already received
antibiotics when samples were obtained, or the culturing
technique might be responsible.29 We have also no sound
explanation for the low frequency of microbiological workups
for case patients, other than the perception of the surgeon
that superficial infections might not require culture samples
to be obtained before empirical antibiotic therapy is started.
This study has some limitations. The sample size was small.
We also have no data on infection rates in the respective
services before January 2000 to determine the baseline in-
fection rate. Furthermore, we did not determine the indi-
cation for implantation, or the indication for performing a
procedure in the cardiothoracic operating room, nor did we
observe long-term outcomes.
The results of our investigation did not identify a common
source to explain the high rate of implantable cardiac device–
associated infections among patients in the cardiothoracic
operating rooms. The explanation for the infection rate was
most likely multifactorial, particularly in light of the multiple
causative organisms identified. During the course of our in-
vestigation, basic infection control measures were taken (eg,
in-service training was provided to operating room staff about
appropriate skin preparation procedures; also, the role of
manufacturers’ representatives in the operating room and the
process they used for handling and passing devices to the
surgeon during surgery were reviewed), and surveillance was
implemented in the affected units. After implementing fun-
damental infection control measures in a unit not previously
audited, we observed decreased infection rates.
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